Evidence Services | library.nhs.uk Search Results Table of Contents Search History ........................................................................................................................................................... page 7 1. [Influence of boric acid on strains of the genus Candida]. .................................................................................... page 8 2. Boric acid treatment of vulvovaginal candidiasis. ................................................................................................. page 8 3. Diaper dermatitis: current concepts. ...................................................................................................................... page 8 4. Treatment of vulvovaginal candidiasis with boric acid powder. ............................................................................ page 9 5. Current therapy of vulvovaginitis. ......................................................................................................................... page 9 6. Torulopsis glabrata vaginitis: clinical aspects and susceptibility to antifungal agents. ....................................... page 10 7. Management of persistent vulvo vaginal candidosis due to azole-resistant Candida glabrata. ........................... page 10 8. Boric acid vaginal suppositories. ......................................................................................................................... page 11 9. Biotypes of oral Candida albicans isolates in human immunodeficiency virus-infected patients from diverse geographic locations. ................................................................................................................................................ page 11 10. Oral Candida albicans biotypes in Chinese patients with and without oral candidosis. .................................... page 12 11. Chronic fungal vaginitis: the value of cultures. ................................................................................................. page 12 12. Treatment of Torulopsis glabrata vaginitis: retrospective review of boric acid therapy. ................................... page 13 13. Successful use of boric acid to control azole-refractory Candida vaginitis in a woman with AIDS. ................ page 13 14. Susceptibility of Candida species isolated from female prostitutes with vulvovaginitis to antifungal agents and boric acid. .......................................................................................................................................................................... page 14 15. Terconazole cream for non-Candida albicans fungal vaginitis: results of a retrospective analysis. .................. page 14 16. Phenotypic characterisation of Candida albicans isolated from chronic hyperplastic candidosis. .................... page 15 17. Biotypes of oral Candida albicans isolated from AIDS patients and HIV-free subjects in Thailand. ............... page 16 18. Candida albicans strain differentiation in complete denture wearers. ............................................................... page 16 19. Candida lusitaniae as an unusual cause of recurrent vaginitis and its successful treatment with intravaginal boric acid. .......................................................................................................................................................................... page 17 20. Boric acid susceptibility testing of non-C. albicans Candida and Saccharomyces cerevisiae: comparison of three methods. ................................................................................................................................................................... page 17 21. Vulvovaginal trichosporonosis. .......................................................................................................................... page 18 22. Phenotypic diversity of oral C. albicans isolated on single and sequential visits in an HIV-infected Chinese cohort. .................................................................................................................................................................................. page 19 23. Common complementary and alternative therapies for yeast vaginitis and bacterial vaginosis: a systematic review. .................................................................................................................................................................................. page 19 24. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. ........................ page 20 25. Biotypes and randomly amplified polymorphic DNA (RAPD) profiles of subgingival Candida albicans isolates in HIV infection. .......................................................................................................................................................... page 21 26. Biotypes and randomly amplified polymorphic DNA (RAPD) profiles of subgingival Candida albicans isolates in HIV infection ........................................................................................................................................................... page 22 27. In vitro activity of bergamot natural essence and furocoumarin-free and distilled extracts, and their associations with boric acid, against clinical yeast isolates ................................................................................................................. page 23 28. In vitro activity of bergamot natural essence and furocoumarin-free and distilled extracts, and their associations with boric acid, against clinical yeast isolates. ................................................................................................................ page 24 29. Vaginal Candida parapsilosis: pathogen or bystander? ...................................................................................... page 24 30. Vaginal Candida parapsilosis: Pathogen or bystander? ...................................................................................... page 25 Page 1 Evidence Services | library.nhs.uk 31. Recurrent vulvovaginal candidiasis ................................................................................................................... page 26 32. Recurrent vulvovaginal candidiasis. .................................................................................................................. page 27 33. Entrapment of lipase in polymer of polyvinyl alcohol-boric acid for esterification in organic media .............. page 27 34. Boric acid for refractory candida glabrata vaginitis ........................................................................................... page 28 35. Boric acid for refractory Candida glabrata vaginitis. ......................................................................................... page 29 36. Candidiasis (vulvovaginal). ............................................................................................................................... page 29 37. Candidiasis (vulvovaginal) ................................................................................................................................ page 30 38. Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis ........................................................................ page 31 39. Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis. ....................................................................... page 32 40. Study on physicochemical properties and pharmacodynamic action of recombinant uricase ........................... page 33 41. Phospholipase, proteinase and haemolytic activities of Candida albicans isolated from oral cavities of patients with type 2 diabetes mellitus ............................................................................................................................................ page 34 42. Prolonged (3-month) mycological cure rate after boric acid suppositories in diabetic women with vulvovaginal candidiasis. ............................................................................................................................................................... page 35 43. Prolonged (3-month) mycological cure rate after boric acid suppositories in diabetic women with vulvovaginal candidiasis ................................................................................................................................................................ page 36 44. Local treatment of vulvovaginal candidosis: General and practical considerations .......................................... page 37 45. Recalcitrant Trichomonas Vaginalis Infections Successfully Treated With Vaginal Acidification ................... page 40 46. Recalcitrant Trichomonas vaginalis infections successfully treated with vaginal acidification ........................ page 41 47. Recalcitrant Trichomonas vaginalis infections successfully treated with vaginal acidification. ....................... page 42 48. Biotypes, genotypes and ketoconazole susceptibility of Candida albicans isolates from a group of Thai AIDS patients ....................................................................................................................................................................